Vistagen Therapeutics VTGN
NASDAQ VTGN
$0.19 -0.01 (-5.00%)
At close: Nov 19, 2026 · 4:00 PM EST

Vistagen Therapeutics (VTGN) Liabilities and Shareholders Equity (2009 - 2026)

Updated

Vistagen Therapeutics' Liabilities and Shareholders Equity was $23.42 million in fiscal Q2 2027 (quarter ended Sep 30, 2026), down 71.1% from $80.93 million a year earlier and down 34.5% from the prior quarter.

Analysis

Vistagen Therapeutics (VTGN) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends

At the end of FY2026 (ended Mar 31, 2026), Liabilities and Shareholders Equity at Vistagen Therapeutics came in at $48.56 million, down 42.4% from FY2025.

  • Liabilities and Shareholders Equity shows a five-year compound annual growth rate of -14.8% (FY2021 to FY2026).
  • In earlier fiscal years, Liabilities and Shareholders Equity was $84.34 million in FY2025 (-31.8%), $123.65 million in FY2024 (+486.3%), $21.09 million in FY2023 (-71.7%) and $74.64 million in FY2022 (-31.1%).
  • The fiscal Q2 2027 figure marks the lowest quarterly Liabilities and Shareholders Equity since fiscal Q1 2024.
  • Compared with a year earlier, Liabilities and Shareholders Equity has declined for eight straight quarters, with an average decline of 39.1% over the last eight quarters.
  • The best year-over-year quarter for Liabilities and Shareholders Equity over five years was fiscal Q1 2025 (growth of 655.4%); the worst was fiscal Q1 2024 (a decline of 74.4%).
  • Per Business Quant data, VTGN's Liabilities and Shareholders Equity in the three fiscal quarters before Q2 2027 was $35.74 million (Q1 2027), $48.56 million (Q4 2026) and $65.06 million (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 PetVivo Holdings 3,096.39 Bn 3,096.39 Bn 196,075.00 2.15 Mn
2 Eli Lilly 1,202.70 Bn 1,176.32 Bn 20.46 Bn 148.07 Bn
3 Johnson & Johnson 649.77 Bn 569.63 Bn 17.30 Bn 197.43 Bn
4 AbbVie 507.00 Bn 475.00 Bn 13.12 Bn 147.68 Bn
5 Merck 329.70 Bn 292.64 Bn 13.19 Bn 132.77 Bn
6 Novartis Ag 291.91 Bn 265.14 Bn - -
7 Amgen 236.26 Bn 187.91 Bn 7.58 Bn 96.05 Bn
8 Gilead Sciences 207.15 Bn 182.26 Bn 6.73 Bn 51.41 Bn
9 Gsk 193.54 Bn 176.38 Bn - 94.88 Bn
10 Vistagen Therapeutics 7.34 Mn -151.60 Mn - 23.42 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 23.42 Mn
Jun 30, 2026 35.74 Mn
Mar 31, 2026 48.56 Mn
Dec 31, 2025 65.06 Mn
Sep 30, 2025 80.93 Mn
Jun 30, 2025 68.92 Mn
Mar 31, 2025 84.34 Mn
Dec 31, 2024 92.31 Mn
Sep 30, 2024 102.50 Mn
Jun 30, 2024 113.55 Mn
Mar 31, 2024 123.65 Mn
Dec 31, 2023 131.07 Mn
Sep 30, 2023 42.20 Mn
Jun 30, 2023 15.03 Mn
Mar 31, 2023 21.09 Mn
Dec 31, 2022 29.71 Mn
Sep 30, 2022 40.70 Mn
Jun 30, 2022 58.73 Mn
Mar 31, 2022 74.64 Mn
Dec 31, 2021 90.54 Mn
API Access

Vistagen Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=VTGN&period=max&api_key=YOUR_API_KEY